Table 2.

Multivariate cox proportional hazards model results for progression-free and overall survival for patients with stage I/II uterine carcinosarcoma.

Variable	Progression-free survival		Overall survival
	HR (95% CI)	p-value	HR (95% CI)	p-value
CT + RT vs. CT	0.43 (0.19–0.95)	0.04	0.94 (0.34–2.65)	0.91
RT vs. CT	0.81 (0.37–1.76)	0.59	2.13 (0.79–5.71)	0.13
OBS vs. CT	1.73 (0.84–3.57)	0.14	4.48 (1.67–12.02)	0.003
Site 4 vs. Site 1	0.41 (0.18–0.91)	0.03	0.28 (0.10–0.77)	0.01
Site 3 vs. Site 1	0.62 (0.36–1.06)	0.08	0.49 (0.26–0.94)	0.03
Site 2 vs. Site 1	0.43 (0.21–0.89)	0.02	0.33 (0.14–0.77)	0.01
Race (White vs. Black/Other)	1.18 (0.71–1.97)	0.53	1.52 (0.82–2.82)	0.19
Cancer history (Yes vs. No)	0.91 (0.51–1.64)	0.76	1.23 (0.62–2.44)	0.55
Residual disease (Yes vs. No)	2.26 (0.49–10.34)	0.30	4.88 (0.97–24.51)	0.05
LVSI (Yes vs. No)	0.80 (0.48–1.35)	0.40	1.29 (0.70–2.36)	0.41
Stage (II vs. I)	3.28 (1.82–5.94)	<0.0001	2.86 (1.47–5.59)	0.002
Age (continuous)	1.03 (1.00–1.05)	0.03	1.01 (0.98–1.04)	0.45
Year of diagnosis (continuous)	1.05 (0.99–1.11)	0.13	1.06 (0.99–1.14)	0.11
Parity (continuous)	0.97 (0.87–1.09)	0.59	1.06 (0.99–1.14)	0.40